We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.05 | -6.06% | 0.775 | 0.75 | 0.80 | 0.825 | 0.775 | 0.83 | 611,345 | 15:32:48 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 0 | -1.03M | -0.0057 | -1.35 | 1.39M |
Date | Subject | Author | Discuss |
---|---|---|---|
03/8/2018 17:28 | Is that the sound of the world's smallest violin? Grow up hugh and stop blaming your situation on 'traders', 'MMs' and 'derampers' .. I'm no efficient market proponent but the price is where it is because of sentiment and the perceived chances of success. Think it's oversold? Then buy more and stop bleating at me for being a bit more skeptical. | dplewis1 | |
03/8/2018 17:10 | Not naive Nobbo, Nigel and myself disagree on a number of things. The effect of traders on a share price not being one of them. Lewis, the deramper. When have you ever done any analytical research. Your sole input on this thread from the day you started is to attack me and everything I say. | hughwilson | |
03/8/2018 17:02 | Hugh and the word naive were made for each other.... | nobbygnome | |
03/8/2018 16:17 | Broker notes only slightly better than garbage on here. They do spell Astrazeneca correctly, only saving grace. | escapetohome | |
03/8/2018 16:04 | dplewis1, so you are entirely negative on any positive. No change there then and what you would expect of a deramper. | hughwilson | |
03/8/2018 14:22 | Haha ..glad I never read those but as ih_ jokingly points out this is a new (bottom tier) broker that also has connections to a substantial shareholder..the rose tinted specs are well and truly on. Granted, it will delve into each area of the business and seem professional but there will also be a lot of fluff about the addressable market size of sildenafil, the potential of the vaccines business etc. There will probably be some finger in the air share price prediction that will get people salivating. But it will not be widely digested and if there's a bump to the share price it could well suffer from 'post recommendation drift' in the weeks after. | dplewis1 | |
03/8/2018 14:20 | looks finished | opodio | |
03/8/2018 14:16 | Check out the brokers' notes from the two weeks before the Carillion news broke! Loads of other examples too. | gettingrichslow | |
03/8/2018 13:44 | ih_575893, Despite your sarcasm, a positive broker note will not have been compiled without due research. | hughwilson | |
03/8/2018 13:39 | Ffs hugh. What you mean the newly appointed broker isn’t going to produce a negative note? Jeez. | ih_575893 | |
03/8/2018 13:00 | OneDayRodders, they will probably say it as Nigel does.They will look at the data, identify the failings and if it can be tweaked then they will do so, and then go for a second trial. | hughwilson | |
03/8/2018 12:53 | That's good to hear hugh Will be even more interesting to hear what part of the business they concentrate on. | onedayrodders | |
03/8/2018 12:43 | I am expecting a highly positive brokers note from the new broker Allenby in the days ahead. | hughwilson | |
03/8/2018 12:12 | No confidence whatsoever in any of these posts. Useless non-information. No confidence in n4p either. | escapetohome | |
02/8/2018 17:12 | Strange widening of the spread at the end, you could still buy 50k at 8.67 if you so desired. Sunny Thursday night in the City..time for a few quick beers I think! | dplewis1 | |
02/8/2018 16:50 | Sweet lord. Let's keep to the topic folks. | jimbobaroony | |
02/8/2018 15:22 | jpsbax, 5 against 1 Where I come from they call that a mugging. | hughwilson | |
02/8/2018 14:51 | Jpsbax Do you now agree that he’s a bell end?? | eddie_yates | |
02/8/2018 11:56 | Nobby, estimated cost of rerunning the trial was touted at around GBP 500k from what I recall. | dplewis1 | |
02/8/2018 11:17 | Yeah, apologies about that. Not as one sided as I first thought. | jpsbax |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions